← Eichor
Condition: Cervical Carcinoma Stage Ii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cervical Carcinoma Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT057869243-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05674396Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinom
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT07188103Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04712851Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
Phase 2 · 1 location(s) · Xiaohua Wu · NCT06209294Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Phase 2 · 1 location(s) · Dallas VA Medical Center · NCT04018872Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours
NA · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT03238378Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT04988074Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT06100497Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06006169De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Phase 2 · 3 location(s) · Mayo Clinic · NCT05541016A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brach
NA · 1 location(s) · Ain Shams University · NCT07343531Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Phase 2 · 1 location(s) · Alain Algazi · NCT03708224BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT06627270LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07325539Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT04221893Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05624099Proton Therapy for Recurrent Nasopharyngeal Carcinoma
NA · 2 location(s) · Guangzhou Concord Cancer Center · NCT07412314Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcino
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161545Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Phase 2 · 13 location(s) · Dana-Farber Cancer Institute · NCT04620187Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07447570Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squa
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07147426Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06323460
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.